Αρχική World News FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma Expressing... World News FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma Expressing PD-L1 (CPS ≥1) Από Ogkologos - 11 Απριλίου, 2025 1409 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-811 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Advancing Cancer Research as a Married Couple: “Your Stories” Podcast 18 Δεκεμβρίου, 2020 Happy 29th Birthday OncoLink! 7 Μαρτίου, 2023 Financial Navigation Can Reduce the Financial Toxicity of Cancer Care 21 Απριλίου, 2023 Health inequalities: Why is it harder for some people to eat... 24 Ιουνίου, 2022 Φόρτωση περισσοτέρων HOT NEWS New Areolar Incision Technique Leaves Almost No Scars for Breast Cancer... A tribute to Professor Anne Charlton Qué saber sobre los diferentes tipos de mastectomías para el cáncer... DeFi Trial: Smart Design and Impressive Results For the Benefit of...